Global Neurocognitive Assessment And Rehabilitation Market Size, Share & Trends Analysis Report By Component (Neurorehabilitation Therapy, and Neurocognitive Assessment Testing), By Providers, By Regional Outlook and Forecast, 2023 - 2030
The Global Neurocognitive Assessment And Rehabilitation Market size is expected to reach $23.6 billion by 2030, rising at a market growth of 8.4% CAGR during the forecast period.
The rising number of senior people and the growing incidence of neurological disorders mainly drive the market in Asia Pacific. Countries such as China, Japan, South Korea, and India are expected to grow considerably over the forecast period. Consequently, the Asia Pacific region would acquire nearly 25% of the total market share by 2030. Cultural attitudes towards mental health and neurological conditions vary widely in the Asia Pacific region. Initiatives should focus on increasing awareness, reducing stigma, and promoting cultural sensitivity regarding neurocognitive health. Some of the factors impacting the market are increasing prevalence of neurological disorders, growing technology advancement in neurocognitive rehabilitation and high cost of technologies and services.
With the increasing awareness of neurological disorders, there is a growing focus on early detection and intervention. Neurocognitive assessment is crucial in identifying cognitive deficits early, allowing for timely and targeted rehabilitation interventions. The surge in neurological disorders has prompted increased research initiatives focused on understanding the underlying mechanisms, hazard factors, and potential interventions. This research contributes to the development of evidence-based assessment tools and rehabilitation strategies. Thus, the increasing number of neurological diseases is a key driver positively influencing the growth of the market. Additionally, advanced neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), enable more precise and detailed brain structure and function assessment. VR and AR technologies have been incorporated into neurocognitive rehabilitation programs. These immersive technologies create realistic environments for cognitive exercises and rehabilitation activities. Therefore, the growing technological advancement is a driving force behind expanding the market.
Moreover, During the pandemic, there was a rapid and widespread adoption of telehealth solutions. Neurocognitive assessments and rehabilitation services transitioned to virtual platforms, allowing healthcare providers to continue delivering care remotely. The pandemic heightened awareness of mental health challenges, including increased stress, anxiety, and depression. This focus on mental health underscored the importance of including neurocognitive assessments in comprehensive mental health evaluations. The market witnessed a shift toward addressing cognitive well-being as an integral component of overall mental health care. Therefore, the pandemic positively impacted the market.
However, the high cost of neurocognitive assessment technologies and rehabilitation services can limit accessibility, particularly for individuals in lower-income brackets or regions with limited healthcare resources. Moreover, the high cost can contribute to inequality in the delivery of neurocognitive care. Affluent individuals or those with better insurance coverage may have greater access to advanced assessments and rehabilitation services, exacerbating existing healthcare disparities. Due to the above factors, the market growth will be hampered in the coming years.
Component Outlook
On the basis of component, the market is segmented into neurocognitive assessment testing and neurorehabilitation therapy. The neurocognitive assessment testing segment acquired a substantial revenue share in the market in 2022. Neurocognitive evaluations often require the cooperation of occupational therapists, speech therapists, neurologists, and neuropsychologists. Implementing this interdisciplinary methodology assures a thorough comprehension of the cognitive well-being of the individual. In some cases, assessments may include measures of emotional and personality functioning. This helps in understanding the impact of cognitive impairments on emotional well-being.
Provider Outlook
Based on providers, the market is fragmented into rehab centers, hospital & clinics, homecare settings, and physiotherapy centers. The homecare settings segment garnered a significant revenue share in the market. This can be attributed to the increasing demand for in-home neurocognitive assessments driven by convenience for caregivers, preventive care focus, individualized treatment plans, pandemic-related changes, and improved technology integration. Home-based neurocognitive care recognizes the importance of addressing emotional and psychosocial aspects. Telehealth counseling sessions and support groups can be arranged to help individuals cope with the emotional challenges associated with cognitive impairment.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region registered the largest revenue share in the market. This can be attributed to a strong emphasis on research & development in the healthcare sector. The region's robust ecosystem of research institutions, medical universities, and private industry players is expected to foster continuous innovation in neurocognitive technologies. Moreover, collaborations between academia and the healthcare industry facilitate the rapid development and adoption of advanced assessment & rehabilitation tools.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cambridge Cognition Holdings plc, Cognifit, Inc., Cogstate Ltd., Lumos Labs, Inc. (Lumosity), CNS Vital Signs, LLC, Posit Science Corporation, BrainCheck, Inc., Constant Therapy Health, NeuronUP SL and SCHUHFRIED GmbH
Scope of the Study
Market Segments covered in the Report:
By Component
- Neurorehabilitation Therapy
- Neurocognitive Assessment Testing
By Providers
- Rehab Centers
- Hospital & Clinics
- Homecare Settings
- Physiotherapy Centers
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Cambridge Cognition Holdings plc
- Cognifit, Inc.
- Cogstate Ltd.
- Lumos Labs, Inc. (Lumosity)
- CNS Vital Signs, LLC
- Posit Science Corporation
- BrainCheck, Inc.
- Constant Therapy Health
- NeuronUP SL
- SCHUHFRIED GmbH
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free